Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Dermatology

Treating Gorlin Syndrome: A Proactive Management Plan

At a Glance

Gorlin syndrome treatment focuses on conservatively managing basal cell carcinomas and recurrent jaw cysts while preserving quality of life. Essential strategies include avoiding radiation therapy, utilizing targeted surgeries, and using Hedgehog inhibitors with scheduled drug holidays to manage side effects.

Managing Gorlin syndrome is a marathon, not a sprint. Because the condition is chronic and symptoms can recur, the goal of treatment is to manage issues as conservatively as possible to preserve your quality of life [1][2]. Your care will likely involve several different approaches tailored to your specific needs.

Protecting Your Skin

The most common challenge in Gorlin syndrome is the frequent development of Basal Cell Carcinomas (BCCs). While these are a form of skin cancer, they are highly treatable [3][4].

  • Topical Treatments and Light Therapy: For superficial (surface-level) skin lesions, doctors may use prescription creams or Photodynamic Therapy (PDT) [4][5]. PDT uses a special light-activated cream to kill cancer cells without the need for cutting the skin, which helps reduce scarring [4].
  • Surgery: For deeper BCCs, traditional excision or Mohs surgery (a specialized technique that removes the cancer layer by layer while sparing healthy tissue) is often used [4][6].
  • A Critical Warning—No Radiation: It is vital to know that therapeutic radiation should NOT be used to treat BCCs in people with Gorlin syndrome [7]. Because of the genetic mutation in the PTCH1 gene, your cells are hypersensitive to radiation, which can trigger a “storm” of hundreds of new skin cancers in the area that was treated [8][9].

Managing Jaw Cysts (OKCs)

Odontogenic Keratocysts (OKCs) are non-cancerous but aggressive cysts in the jaw. Because they often return, surgeons use several strategies to remove them and prevent recurrence [10][11]:

  • Decompression (Marsupialization): For large cysts, a surgeon may first create a small opening to allow the cyst to drain and shrink over several months [12][13]. This makes the final removal surgery much safer for the jawbone and teeth [12].
  • Enucleation and Adjuncts: The cyst is carefully “scooped out” (enucleated). To kill any remaining microscopic cells and prevent recurrence, the surgeon may apply a special solution (like Modified Carnoy’s solution or topical 5-fluorouracil) or perform a “peripheral ostectomy” (lightly sanding the bone) [14][15].

Oral Medications (SMO Inhibitors)

For patients with a high number of BCCs or advanced lesions that cannot be managed by surgery alone, a class of drugs called Hedgehog pathway inhibitors (such as vismodegib or sonidegib) may be used [16][17].

These “smart drugs” work by manually turning off the cell-growth engine that is stuck “on” in Gorlin syndrome [18]. While highly effective at shrinking tumors and preventing new ones, they come with significant considerations:

A Critical Warning—Severe Risk of Birth Defects:
Hedgehog inhibitors are highly teratogenic, meaning they cause severe, life-threatening birth defects. Both men and women must use strict, highly effective birth control while taking these medications and for a significant period after stopping [19][16].

Managing Daily Side Effects:
Common side effects include:

  • Muscle cramps
  • Loss of taste (dysgeusia)
  • Hair loss (alopecia) [19][20].

To manage these quality-of-life impacts, many doctors use intermittent dosing or a “drug holiday” strategy [19][21]. This means you might take the medication for a few months and then take a scheduled break to allow your body (and taste buds) to recover before starting again [22][23]. This approach helps patients stay on the treatment for much longer than they could with daily use [19][21].

Common questions in this guide

Why can't I have radiation therapy for skin cancers with Gorlin syndrome?
Radiation therapy should never be used to treat basal cell carcinomas in people with Gorlin syndrome. Because of a specific genetic mutation, your cells are highly sensitive to radiation, which can trigger hundreds of new skin cancers in the treated area.
What is the safest surgical option for recurrent jaw cysts?
Odontogenic keratocysts (OKCs) are often managed with decompression to shrink the cyst first. Afterward, an oral surgeon can safely remove the cyst using enucleation, often applying special solutions to kill remaining microscopic cells and protect your jawbone and teeth.
What are Hedgehog pathway inhibitors like vismodegib used for?
These oral medications are used for patients with numerous or advanced basal cell carcinomas that cannot be managed with surgery alone. They work by shutting down the specific cellular engine that drives tumor growth in Gorlin syndrome.
How can I manage the side effects of medications like vismodegib?
Common side effects like muscle cramps, hair loss, and loss of taste can heavily impact your daily life. To manage this, many doctors use an intermittent dosing strategy or scheduled 'drug holidays' to give your body a break while still controlling the skin cancers.
Do I need to use birth control while taking Hedgehog inhibitors?
Yes. These medications carry a severe risk of causing life-threatening birth defects. Both men and women must use strict, highly effective birth control while on the medication and for a significant period after stopping.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the most conservative surgical option for my current jaw cysts to protect my jawbone and teeth?
  2. 2.If we use a Hedgehog inhibitor, can we start with an intermittent dosing schedule or a 'drug holiday' plan from the beginning?
  3. 3.Are there topical treatments or light-based therapies (PDT) we should try before considering more invasive surgery for my skin?
  4. 4.How do we ensure that no one on my care team accidentally recommends radiation therapy for my skin lesions?
  5. 5.Which oral surgeon in our area has the most experience treating syndromic (multiple) jaw cysts?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Genetic aspects of Gorlin‒Goltz syndrome

    Vetró É, Oláh J, Nagy D, et al.

    Orvosi hetilap 2020; (161(49)):2072-2077 doi:10.1556/650.2020.31933.

    PMID: 33279882
  2. 2

    A Rare Case of Gorlin-Goltz Syndrome in Children.

    Boos Lima FBDJ, Viana APC, Lima LHF, et al.

    Case reports in dentistry 2019; (2019()):1608783 doi:10.1155/2019/1608783.

    PMID: 31934460
  3. 3

    Multidisciplinary approach to Gorlin-Goltz syndrome: from diagnosis to surgical treatment of jawbones.

    Spadari F, Pulicari F, Pellegrini M, et al.

    Maxillofacial plastic and reconstructive surgery 2022; (44(1)):25 doi:10.1186/s40902-022-00355-5.

    PMID: 35843976
  4. 4

    5-aminolevulinic acid photodynamic therapy and excision surgery for nevoid basal cell carcinoma syndrome with multiple basal cell carcinomas and PTCH1 mutation.

    Li C, Chen P, Li Z, et al.

    Photodiagnosis and photodynamic therapy 2020; (32()):101968 doi:10.1016/j.pdpdt.2020.101968.

    PMID: 32835883
  5. 5

    Ingenol Mebutate Treatment in a Patient with Gorlin Syndrome.

    Stieger M, Hunger RE

    Dermatology (Basel, Switzerland) 2016; (232 Suppl 1()):29-31 doi:10.1159/000447394.

    PMID: 27513585
  6. 6

    Nevoid Basal Cell Carcinoma Syndrome: Clinical Features, Treatment, and Diagnostic Criteria.

    Zhang T, Chen R, Guo S

    The Journal of craniofacial surgery 2022; (33(6)):e557-e559 doi:10.1097/SCS.0000000000008445.

    PMID: 36054895
  7. 7

    Gorlin-Goltz syndrome.

    Şereflican B, Tuman B, Şereflican M, et al.

    Turk pediatri arsivi 2017; (52(3)):173-177 doi:10.5152/TurkPediatriArs.2017.2992.

    PMID: 29062253
  8. 8

    Severe PATCHED1 Deficiency in Cancer-Prone Gorlin Patient Cells Results in Intrinsic Radiosensitivity.

    Vulin A, Sedkaoui M, Moratille S, et al.

    International journal of radiation oncology, biology, physics 2018; (102(2)):417-425 doi:10.1016/j.ijrobp.2018.05.057.

    PMID: 30191873
  9. 9

    Novel PTCH1 mutations in Japanese familial nevoid basal cell carcinoma syndrome.

    Nakase Y, Hamada A, Kitamura N, et al.

    Human genome variation 2020; (7(1)):38 doi:10.1038/s41439-020-00126-6.

    PMID: 33298892
  10. 10

    Recurrence Patterns of Odontogenic Keratocysts in Syndromic and Non-Syndromic Patients.

    Van Cleemput T, Jackers X, Piagkou M, Politis C

    Journal of maxillofacial and oral surgery 2024; (23(1)):152-158 doi:10.1007/s12663-023-01920-9.

    PMID: 38312954
  11. 11

    Clinical, radiographic, pathological and inherited characteristics of odontogenic keratocyst in nevoid basal cell carcinoma syndrome: a study in three Chilean families.

    Castillo-Tobar A, Urzúa B, Tirreau V, et al.

    Oral radiology 2023; (39(3)):518-527 doi:10.1007/s11282-022-00664-5.

    PMID: 36436193
  12. 12

    Clinical and histomorphometric evaluation of decompression followed by enucleation in the treatment of odontogenic keratocyst.

    Oh JS, You JS, Kim SG

    Journal of dental sciences 2018; (13(4)):329-333 doi:10.1016/j.jds.2018.06.001.

    PMID: 30895141
  13. 13

    Conservative surgical treatments for nonsyndromic odontogenic keratocysts: a systematic review and meta-analysis.

    de Castro MS, Caixeta CA, de Carli ML, et al.

    Clinical oral investigations 2018; (22(5)):2089-2101 doi:10.1007/s00784-017-2315-8.

    PMID: 29264656
  14. 14

    Management and recurrence of the odontogenic keratocyst: an overview of systematic reviews.

    Gonçalves TOF, Rangel RMR, Marañón-Vásquez GA, et al.

    Oral and maxillofacial surgery 2024; (28(4)):1457-1478 doi:10.1007/s10006-024-01277-4.

    PMID: 38954313
  15. 15

    Role of Carnoy's solution in the treatment of keratocystic odontogenic tumor: A systematic review.

    Díaz-Belenguer Á, Sánchez-Torres A, Gay-Escoda C

    Medicina oral, patologia oral y cirugia bucal 2016; (21(6)):e689-e695 doi:10.4317/medoral.21250.

    PMID: 27475699
  16. 16

    Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

    Tang JY, Ally MS, Chanana AM, et al.

    The Lancet. Oncology 2016; (17(12)):1720-1731 doi:10.1016/S1470-2045(16)30566-6.

    PMID: 27838224
  17. 17

    Amenorrhea secondary to vismodegib: An adverse event to consider especially in female patients with Gorlin-Goltz syndrome.

    Russo F, Provvidenziale L, Mancini V, et al.

    Dermatologic therapy 2020; (33(4)):e13527 doi:10.1111/dth.13527.

    PMID: 32383228
  18. 18

    Real-world experience with vismodegib and sonidegib in advanced basal cell carcinoma: a multicenter Italian study.

    Valenti M, Di Giulio S, Carugno A, et al.

    Dermatology reports 2025; (17(3)) doi:10.4081/dr.2025.10196.

    PMID: 39964052
  19. 19

    Oral smoothened inhibitors for Gorlin syndrome: A clinical review.

    Baczynski A, Cahn B, Worley B, et al.

    Journal of the American Academy of Dermatology 2024; (91(4)):706-711 doi:10.1016/j.jaad.2024.06.047.

    PMID: 38950707
  20. 20

    Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib.

    Kumari A, Ermilov AN, Grachtchouk M, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2017; (114(48)):E10369-E10378 doi:10.1073/pnas.1712881114.

    PMID: 29133390
  21. 21

    Alternate Dosing Regimens for Vismodegib: A Literature Review.

    Yang K, Ho-Pham H, Pieper C, et al.

    Current treatment options in oncology 2025; (26(7)):587-591 doi:10.1007/s11864-025-01332-6.

    PMID: 40418287
  22. 22

    Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma.

    Lear JT, Dummer R, Guminski A

    Oncotarget 2021; (12(26)):2531-2540 doi:10.18632/oncotarget.28145.

    PMID: 34966484
  23. 23

    Eight Years of Real-Life Experience with Smoothened Inhibitors in a Swiss Tertiary Skin Referral Center.

    Grossmann LE, Ramelyte E, Nägeli MC, Dummer R

    Cancers 2022; (14(10)) doi:10.3390/cancers14102496.

    PMID: 35626100

This page provides information on Gorlin syndrome treatments for educational purposes only. Always consult your dermatologist, oral surgeon, or oncologist to determine the safest treatment plan for your specific needs.

Get notified when new evidence is published on Gorlin syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.